非肝切除阿片类药物削减措施对肝切除术后阿片处方的影响:2005例分析
该回顾性队列研究纳入2005例连续肝切除患者,按5个阿片类药物方案更新时代分组,分析从胰切除扩展至肝切除的阿片削减措施效果。结果显示术中、住院总及出院阿片口服吗啡当量中位数均显著下降,出院无阿片处方比例从8%升至43%,且出院疼痛评分临床相似。
要点
- 肝切除患者术中及住院总阿片口服吗啡当量中位数下降超过50%。
- 出院阿片口服吗啡当量中位数从225 mg降至60 mg,降幅73%。
- 出院无阿片处方比例从8%升至43%,出院疼痛评分保持1-2分。
核心结论
- 针对胰切除的阿片削减措施对肝切除术后住院及出院阿片用量产生有临床意义的降低,科室内削减措施可产生光环效应。
研究设计与样本
- 回顾性队列研究,使用电子健康记录和前瞻性质量改进数据库,纳入2005例连续肝切除患者(2016年9月至2024年2月),按5个阿片相关方案更新时代分组。
主要发现
- 2005例患者中31%接受大范围肝切除,14%中等范围,46%小范围,9%联合手术/其他;79%通过开腹入路。
- 住院中位时间从E1的5天降至E5的4天。
- 术中阿片口服吗啡当量中位数从E1的80 mg降至E5的37 mg(p < 0.001),住院总中位数从181 mg降至86 mg(p < 0.001)。
- 出院阿片口服吗啡当量中位数从E1的225 mg降至E5的60 mg(p < 0.001),降幅73%,出院疼痛评分临床相似(1-2分/10)。
- 常规3药非阿片出院处方的普遍采用率从E1的70%升至E5的98%,与出院无阿片患者比例从8%升至43%相关(p < 0.001)。
临床怎么用
- 可将胰切除阿片削减方案扩展至肝切除患者,以减少术中、住院及出院阿片用量而不增加出院疼痛评分。
- 推广常规3药非阿片出院处方可能有助于提高肝切除术后无阿片出院比例。
局限性
- 为回顾性队列研究,按历史时代分组,可能存在时间偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pathway-driven, postpancreatectomy opioid reduction interventions have proven effective and sustainable and may have a "halo effect" on other major abdominal cancer operations. This study aimed to analyze the sequential effects of expanding opioid reduction efforts from pancreatectomy on opioids prescribed after hepatectomy. STUDY DESIGN: This was a retrospective cohort study using data from the electronic health record and a prospective quality improvement database for consecutive hepatectomy patients (September 2016 to February 2024). Cohorts were based on 5 distinct eras of opioid-related protocol updates E1 (preintervention historical baseline): September 2016 to March 2017; E2 (introduction of 5x-multiplier): April 2017 to September 2018; E3 (departmental opioid education program): October 2018 to December 2019; E4 (initial posthepatectomy pathways): January 2020 to June 2022; and E5 (updated pancreatectomy pathways influencing hepatectomy care): July 2022 to February 2024). RESULTS: Of 2,005 patients, 31% underwent major hepatectomy, 14% intermediate, 46% minor, and 9% combination surgery/other. Most (79%) patients were performed via an open approach. The median hospital stay decreased from 5 to 4 days between E1 and E5. Both intraoperative (E1, 80 mg; E5, 37 mg; p < 0.001) and total inpatient (E1 181 mg, E5 86 mg; p < 0.001) median oral morphine equivalents were reduced by >50%. A 73% reduction in discharge oral morphine equivalents was observed between E1 (225 mg) and E5 (60 mg; p < 0.001), with clinically similar median pain scores at discharge (scores 1 to 2 of 10). Concurrent universal adoption of routine 3-drug nonopioid discharge prescriptions (E1 70%, E5 98%) correlated with the proportion of patients discharged opioid-free (E1 8%, E5 43%; p < 0.001). CONCLUSIONS: Directed opioid reduction efforts for pancreatectomy influenced clinically meaningful posthepatectomy reductions in inpatient and discharge opioid volumes. A "halo effect" of intradepartmental opioid reduction efforts is attainable and corresponds to measurable increases in opioid-free or nearly opioid-free discharges after major abdominal cancer surgery.
引用
- Fields BC, Newhook TE, Prakash LR, et al. Impact of Nonhepatectomy Opioid Reduction Efforts on Posthepatectomy Opioid Prescription: Analysis of 2,005 Patients. J Am Coll Surg. 2025. PMID: 39807798. doi:10.1097/XCS.0000000000001279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。